The round was led by FCA Venture Partners, with the Labcorp Venture Fund and Epsilon anchoring the final close as the primary investors. Strong participation also came from existing investors, ...

The company's presence highlights Dublin’s growing reputation as a destination for innovation, connectivity and business ...

The Dublin-based firm is developing an array of artificial intelligence-derived tools to improve the efficiency of its digital pathology outsourcing service.

Q3 2025 Earnings Call Transcript October 28, 2025 Labcorp Holdings Inc. beats earnings expectations. Reported EPS is $4.18, ...

Its full-year revenue growth forecast was also trimmed and is now expected to be in the range of 7.4% to 8%, down from ...

Shares of Labcorp Holdings Inc. shed 5.79% to $259.69 Tuesday, on what proved to be an all-around positive trading session ...

Labcorp posts Q3 EPS of $4.18 and sales of $3.56 billion, exceeding estimates, while revising 2025 guidance amid strong ...

As a leading independent diagnostic laboratory, Labcorp participates in a highly attractive duopoly that offers favorable prospects as healthcare moves toward reformed payment models, Medicare ...

BLS revenue reached $799 million, up 8.3%, and adjusted operating income grew to $132 million. The quarter ended with an $8.6 billion backlog, and the BLS book-to-bill was 0.89 for the quarter and ...

AI-driven diagnostic efficiency streamlines lab test selection, reducing clinician workload and enhancing patient care at health systems.

Total revenues for the three months ended Sept. 30 were $3.56 billion, up from $3.28 billion in the third quarter of 2024 and matching the consensus Wall Street estimate.

Guidance Updates -- Full-year 2025 revenue growth guidance was narrowed to 7.4%-8%, with Adjusted EPS guidance was set at $16 ...